JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Vagnerova, K. Articles by Kirsch, J. R. Search for Related Content PubMed PubMed Citation Articles by Vagnerova, K. Articles by Kirsch, J. R. Related Collections Mechanisms Neuroanesthesia Pharmacology

---

NEUROSURGICAL ANESTHESIA

Sigma 1 Receptor Agonists Act as Neuroprotective Drugs Through Inhibition of Inducible Nitric Oxide Synthase

From the Department of Anesthesiology and Peri-Operative Medicine, Oregon Health and Science University, Portland, Oregon.

Address correspondence and reprint requests to Jeffrey R. Kirsch, MD, Professor, Department of Anesthesiology and Peri-Operative Medicine, OHSU, 3181 SW Sam Jackson Park Road UHS-2, 97239, Portland, OR 97239. Address e-mail to kirschje{at}ohsu.edu.

Postischemic administration of the sigma-1 agonists reduces ischemic brain injury; however, the mechanism is unclear. We hypothesized that the sigma-1 agonist (+)isoform of pentazocine (P(+)) reduces damage in part by ameliorating cell death mediated via inducible nitric oxide synthase (iNOS) and that the (–)isoform (P(–)) lacks this effect. We compared treatment with P(+) with or without the iNOS inhibitor aminoguanidine (AG) and also the effects of P(+) in iNOS deficient (iNOSKO) mice. A possible mechanism of neuroprotection is inhibition of iNOS expression. Male C57/Bl6 mice were subjected to transient middle cerebral artery occlusion (90 min) and drugs were administered with reperfusion: 1) P(+) with AG (P+/AG), 2) P(+), 3) P(–), 4) AG, or 5) placebo. iNOSKOs were treated with either P(+) or placebo. Infarction (triphenyltetrazolium chloride histology, 72 h) was reduced by P(+) treatment in striatum by 44% and in neocortex by 23% versus placebo (P < 0.05), a reduction comparable to AG effect. P(–) did not attenuate brain injury. There was no difference in P(+)/AG treatment compared with showed the same level of neuroprotection as P(+) alone. P(+) also did not provide further neuroprotection for iNOSKOs. We conclude that postischemic administration of P(+) reduces infarct volume in mice. Because AG provides no additional benefit to P(+) treatment and iNOSKOs do not benefit from P(+), we speculate that P(+) acts by suppressing cell death resulting from iNOS toxicity.

This article has been cited by other articles:

				S. B. Smith, J. Duplantier, Y. Dun, B. Mysona, P. Roon, P. M. Martin, and V. Ganapathy In Vivo Protection against Retinal Neurodegeneration by Sigma Receptor 1 Ligand (+)-Pentazocine Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4154 - 4161. [Abstract] [Full Text] [PDF]

				Y. Dun, M. Thangaraju, P. Prasad, V. Ganapathy, and S. B. Smith Prevention of Excitotoxicity in Primary Retinal Ganglion Cells by (+)-Pentazocine, a Sigma Receptor-1 Specific Ligand Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4785 - 4794. [Abstract] [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999